4//SEC Filing
DelMar Pharmaceuticals, Inc. 4
Accession 0001013762-16-001539
$HURACIK 0001498382operating
Filed
May 2, 8:00 PM ET
Accepted
May 3, 5:02 PM ET
Size
6.3 KB
Accession
0001013762-16-001539
Insider Transaction Report
Form 4
Mohr Erich
Director
Transactions
- Purchase
Series B Preferred Stock
2016-04-29$8.00/sh+9,375$75,000→ 9,375 totalFrom: 2016-04-29→ Common Stock (93,750 underlying)
Footnotes (3)
- [F1]The Series B Preferred stock is convertible into such number of shares of common stock equal to the number of Preferred Shares to be converted, multiplied by the Stated Value of $8.00, divided by the Conversion Price in effect at the time of the conversion (the initial Conversion Price will be $0.80, subject to adjustment in the event of stock splits, stock dividends, and similar transactions).
- [F2]The Reporting Person purchased Series B Preferred Stock from the Company in a private placement on April 29, 2016 (the "Private Placement").
- [F3]The Series B Preferred Stock will automatically convert to common stock at the earlier of (a) the Company's lead product candidate, VAL-083, receiving Food and Drug Administration or European Medicines Agency approval (provided that, at the time of such approval, the closing bid price of the common stock is at least $2.00 (subject to adjustment for stock splits or stock dividends) or (b) five years from the final closing of the Private Placement.
Documents
Issuer
DelMar Pharmaceuticals, Inc.
CIK 0001498382
Entity typeoperating
IncorporatedNV
Related Parties
1- filerCIK 0001498382
Filing Metadata
- Form type
- 4
- Filed
- May 2, 8:00 PM ET
- Accepted
- May 3, 5:02 PM ET
- Size
- 6.3 KB